N	Concordance
1	end point to study the influence of new induction therapies on residual resistan
2	ct a pathologic complete response after induction therapy accurately, suggesting
3	ditional 20% received CAP with antibody induction therapy (OKT3 or ALG). After 1
4	ate the efficacy of this combination as induction therapy in patients with local
5	.  Most therapists recommend continuing induction therapy for at least 12 months
6	ve neither objective response following induction therapy clearly correlated wit
7	s part of a quadruple immunosuppressive induction therapy following orthotopic l
8	ssion receive  a second 5-day course of induction therapy beginning upon hematol
9	therapeutic regimens such as the use of induction therapy and combination therap
10	 receptor antibody as part of quadruple induction therapy after orthotopic liver
11	atic molecular markers during remission induction therapy with all-trans retinoi